ArticleAdvances in therapy2026

Pharmacokinetics, Safety, and Immunogenicity of DMB-3115, a Ustekinumab Biosimilar for Immune-Mediated Diseases, in Healthy Japanese Male Participants: A Randomized, Double-Blind, Single-Dose Study.

Hironori Konishi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.